Howard Mandell, MD
Neurology · Rock Hill, SCNPI 1316939697
Payments from drug & device makers
Across 1,316 payments — averaging $770.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$580K
- UCB SA$102K
- Alkermes, Inc.$100K
- Biogen$93K
- AbbVie$38K
- Adamas Pharmaceuticals, Inc.$33K
- plus $67K from 54 others
Across 2 payments — averaging $2622.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$5K
What the payments were for
- Speaking & faculty fees$490%
- Food & beverage$20,24498%
- Education$4532%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,014,342 in reported general payments places this provider in the 95th percentile of 270 neurology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 66 | $454,418 |
| AustedoDeutetrabenazine | 15 | $181,290 |
| Kesimpta PenOfatumumab | 21 | $179,471 |
| Nurtec OdtRimegepant Sulfate | 80 | $108,831 |
| BetaseronInterferon Beta-1b | 11 | $107,496 |
| BriviactBrivaracetam | 55 | $104,695 |
| VumerityDiroximel Fumarate | 11 | $104,573 |
| Teriflunomide | 27 | $101,667 |
| ZeposiaOzanimod Hydrochloride | 11 | $99,741 |
| CopaxoneGlatiramer Acetate | 13 | $74,599 |
| QuliptaAtogepant | 58 | $65,984 |
| Keppra XrLevetiracetam | 17 | $64,202 |
| UbrelvyUbrogepant | 40 | $56,623 |
| FingolimodFingolimod Hcl | 27 | $38,270 |
| RexultiBrexpiprazole | 20 | $32,110 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $4,440 | $454,41866 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Copaxone | $773 | $255,88828 claims |
| PfizerNurtec Odt, Eliquis | $995 | $132,657107 claims |
| UCB, Inc.Briviact, Vimpat | $806 | $131,43667 claims |
| AbbVieQulipta, Ubrelvy | $38,269 | $122,60698 claims |
| BiogenVumerity | $92,540 | $104,57311 claims |
| E.r. Squibb & Sons, L.L.C.Zeposia | $91 | $99,74111 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $378 | $32,11020 claims |
| Supernus Pharmaceuticals, Inc.Trokendi Xr | $467 | $15,17422 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $385 | $6,10116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 270 neurology providers in South Carolina.
Other neurology in Rock Hill
- Harold ReevesRock Hill$23K
- Mary HughesGreenville$6.3M
- William McElveenColumbia$3.7M
- Robert CarlileSummerville$2.3M
- Andrew KeeganCharleston$2.2M
- Paul MazzeoPort Royal$1.7M
- Vanessa HinsonCharleston$1.5M
- David SticklerNorth Charleston$1.2M
- Katherine RuzhanskyCharleston$1.1M
- Nicholas MilanoCharleston$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.